Be Familiar With the Latest Oral Multiple Sclerosis Meds

November 2020

You’ll hear about a flurry of new ORAL meds to treat multiple sclerosis (MS)...such as Mayzent, Vumerity, and Zeposia.

Expect patients with relapsing-remitting MS to usually start treatment right away...to reduce flares and slow progression.

We’re used to seeing the injectables (Avonex, Copaxone, etc) first-line. Or patients with more severe disease may jump right to a monoclonal antibody IV infusion (Lemtrada, Tysabri, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Point Out Limitations of COVID-19 Antibody Testing
Substance Use Disorder Stay Alert for Unexpected Rx and OTC Med Misuse
Asthma Don’t Jump to Trelegy for Asthma
Fever Improve Accuracy of Noncontact Infrared Thermometers
Practice Evaluate if Guidelines “Fit” Your Patients
Supplements Clear Up Confusion About “Memory Supplements”
Med Administration Know When to Give Patients a “Green Light” to Cut or Crush Meds
Multiple Sclerosis Be Familiar With the Latest Oral Multiple Sclerosis Meds
Depression Offer Resources for Perinatal Depression
Medicare Expect Changes for Medicare Part D in 2021
Infectious Diseases Answer Questions About Using Steroids for COVID-19
Hemorrhage Optimize Safe Use of IV Tranexamic Acid
Infectious Diseases Sort Through Options for ESBL, CRE, and Resistant Pseudomonas
Nausea & Vomiting Combine Antiemetics and Peri-Op Strategies for PONV Prophylaxis

Be Familiar With the Latest Oral Multiple Sclerosis Meds

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents